SUBSCRIBE: Print / eNewsletter
Midostaurin in FLT3-Mutated AML: Results of the RATIFY Trial
In this interview we discuss results of the CALGB 10603 RATIFY trial of midostaurin for acute myeloid leukemia presented earlier this month at ASH.
Ponatinib Improves Survival Over SCT in Chronic-Phase CML
Ponatinib offered a better overall survival for chronic myeloid leukemia patients in chronic phase compared with allogeneic stem cell transplantation.
First-Line Ibrutinib Delayed CLL Progression, Death in Older Patients
Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.
Warfarin Another Option for Cancer-Associated Thrombosis
Warfarin is an acceptable alternative to low-molecular-weight heparin for patients with cancer-associated thrombosis, according to a new study.
Real-Time Classification Finds High-Risk ALL With Favorable Outcomes
Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.
Guidelines Validated for Anticoagulant Dose Reductions in Thrombocytopenia
A new study validates therapeutic guidelines that recommend anticoagulant dose reductions for thrombocytopenia in cancer patients.
Many Children With ALL Do Not Take Medicine as Directed
Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.
Venetoclax Improved Response in High-Risk Relapsed, Refractory CLL
The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.
Daratumumab Combo Safe, Durable in Relapsed/Refractory Myeloma
Patients with relapsed/refractory multiple myeloma continue to have deep and durable responses to daratumumab plus lenalidomide/dexamethasone.
Idelalisib Combo Delays Progression, Death in Relapsed, Refractory CLL
Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.